PR Newswire Europe - Two-Year Data From the Rimonabant in Obesity (RIO)-Europe Study to be Announced at the American College of Cardiology Scientific Session 2005 in Orlando,…
ORLANDO, Florida, March 4 /PRNewswire/ — Obesity is a major public health burden and a key risk factor for the development of cardiovascular disease, the leading cause of mortality worldwide.(1)
The 2-year RIO-Europe trial is one of four Phase III studies comprising the RIO programme, which assesses the efficacy and safety of rimonabant, the first in a new class of therapeutic agents called CB1-blockers.
Related Results
Cheyenne, Wyo.-area doctors skeptical of ’super bill’ for weight loss, smoking.
Pounds-off prescription
FDA Shouldn’t Approve Diet Drug, Panel Says
Pill could help obesity and smoking.(News)(Brief Article)
Shares in Sanofi fall after anti-obesity drug setback
WHAT: Two-Year Data from the RIO-Europe Study: Metabolic Effects of
Rimonabant in Overweight/Obese Patients
WHO: Luc Van Gaal M.D., PhD
…
Read the rest of this article with a Free Trial at HighBeam Research.
